Changes in Pituitary Iron and Volume With Deferasirox

Completed

• Conditions: Iron Overload

• Registration Number: NCT01376622
• Lead Sponsor: Children's Hospital Los Angeles

Brief Summary

Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2011-06-17
• Study First Submitted QC: 2011-06-17
• Study First Posted: 2011-06-20
• Primary Completion: 2011-07-01
• Study Completion: 2011-07-01
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-27
• Last Update Posted: 2023-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Currently on chronic transfusion therapy.
• Duration of chronic transfusion >1 year.
• Age 2 to 25 years
• On deferasirox monotherapy for the duration of the study.
• Informed consent from legal guardian and/or patient.
• On deferasirox for a minimum of 3 months at start of study.

Exclusion Criteria

• Sickle cell disease or sickle-beta zero genotype.
• Combination of deferasirox and another iron chelator.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Children's Hospital Los Angeles; 🇺🇸 Los Angeles, California, United States